Neuronal nicotinic acetylcholine receptor alpha-3 alpha-5 beta-4 subtype (α3α5β4 nAChR)

The Neuronal nicotinic acetylcholine receptor alpha-3 alpha-5 beta-4 (α3α5β4) subtype is a heteropentameric ligand-gated ion channel that serves as a critical mediator of cholinergic signaling in both the peripheral and central nervous systems. It is primarily composed of α3 and β4 subunits, with the α5 subunit acting as an accessory component that significantly modulates the receptor's biophysical properties, including its calcium permeability and sensitivity to agonists (UniProt P30532, P32297, P30926). In the peripheral nervous system, this receptor subtype is the predominant form in autonomic ganglia, where it facilitates fast excitatory synaptic transmission. In the central nervous system, it is localized in regions such as the medial habenula and interpeduncular nucleus, playing a key role in the neural circuitry that regulates nicotine intake and withdrawal (PubMed: 21248128). Genetic variants within the CHRNA5-CHRNA3-CHRNB4 gene cluster, most notably the rs16969968 polymorphism, have been robustly associated with nicotine dependence, smoking heaviness, and an increased susceptibility to lung cancer and chronic obstructive pulmonary disease (COPD) (PubMed: 18414406). Pharmacological agents such as varenicline and cytisine target this receptor as partial agonists to aid in smoking cessation, while ganglionic blockers like hexamethonium and mecamylamine act as antagonists. A major challenge in developing drugs for this target is achieving selectivity to avoid systemic autonomic side effects, such as hypotension and gastrointestinal distress, which arise from non-specific ganglionic blockade.

Other names

α3β4α5 nAChRCHRNA3/CHRNA5/CHRNB4 receptor complexGanglionic nicotinic receptor15q25 nicotinic receptor clusteralpha3beta4alpha5 nicotinic receptor

Agonist, partial agonist, and antagonist/channel blocker.